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Summary
 
Atherosclerotic vascular lesions are considered to be a major cause of ischemic diseases, includ-
ing myocardial infarction and stroke. Platelet adhesion and aggregation during ischemia–reper-
fusion are thought to be the initial steps leading to remodeling and reocclusion of the postischemic
vasculature. Nitric oxide (NO) inhibits platelet aggregation and smooth muscle proliferation. A
major downstream target of NO is cyclic guanosine 3
 
9
 
,5
 
9
 
-monophosphate kinase I (cGKI). To
test the intravascular significance of the NO/cGKI signaling pathway in vivo, we have studied
platelet–endothelial cell and platelet–platelet interactions during ischemia/reperfusion using
cGKI-deficient (cGKI
 
2/2
 
) mice. Platelet cGKI but not endothelial or smooth muscle cGKI is
essential to prevent intravascular adhesion and aggregation of platelets after ischemia. The de-
fect in platelet cGKI is not compensated by the cAMP/cAMP kinase pathway supporting the
essential role of cGKI in prevention of ischemia-induced platelet adhesion and aggregation.
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U
 
nder physiological conditions, the endothelial cell layer
acts as a nonthrombogenic surface. However, in re-
sponse to pathological stimuli, both endothelial cells and
platelets may become proadhesive/procoagulant, leading
to platelet adhesion to the endothelium and to subsequent
platelet aggregation. Nitric oxide (NO)
 
1
 
 is of major im-
portance for the homeostasis of platelet–endothelium and
platelet–platelet interactions under both physiological and
pathophysiological conditions (1). NO regulates vascular
tone (2) and, together with prostacyclin, inhibits adhesion,
activation, and aggregation of platelets to injured endothe-
lial cells (3, 4). Although most of the NO effects on plate-
lets are thought to be mediated by activation of a soluble
guanylyl cyclase and a subsequent rise in intracellular cyclic
guanosine 3
 
9
 
,5
 
9
 
-monophosphate (cGMP) (5), the exact
pathway involved in mediating NO-dependent inhibition
of platelet adhesion/aggregation remains controversial.
cGMP kinase I (cGKI) is one of the established down-
stream targets of the NO/cGMP signaling cascade. Plate-
lets, as well as endothelial cells, express high concentrations
of cGKI (6–8). In vitro cGMP acting via cGKI lowers cy-
tosolic Ca
 
2
 
1
 
 concentrations in platelets, inhibits platelet ac-
tivation by potent agonists, and initiates phosphorylation of
target proteins, including the vasodilator-stimulated phos-
phoprotein (VASP) and the thromboxane receptor (9–11).
However, the in vivo importance of cGKI-dependent sig-
naling for the homeostasis of platelet–endothelium interac-
tions remains to be established, since an identical role has
been assigned to the prostacyclin/cAMP/cAMP kinase
(cAK) pathway (12).
Interactions between circulating platelets and the vascu-
lar wall are required for maintenance of vascular integrity
and hemostasis. However, in certain pathophysiological
processes, particularly ischemia/reperfusion (I/R), the ad-
hesion and aggregation of platelets may also contribute to
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vascular injury (13–16). After I/R, platelets are recruited to
the postischemic vasculature early after the onset of reper-
fusion (17), leading to luminal narrowing and eventually
reocclusion (18–20). To evaluate the biological role of cGKI
in the homeostasis of platelet–endothelial cell and platelet–
platelet interactions in vivo, we have analyzed platelet ad-
hesion and aggregation during I/R using a cGKI negative
mouse line (8).
 
Materials and Methods
 
Animals.
 
cGKI-deficient (cGKI
 
2/2
 
) mice were generated as
previously described (8) and bred and maintained at the animal
facility of the Institut für Pharmakologie und Toxikologie (TU
München). For experiments, 4–8-wk-old wild-type and cGKI
 
2/2
 
mice of either sex on 129sv background were used (litter- or age-
matched animals). All experimental procedures performed on these
mice were approved by the German legislation on protection of
animals.
 
Western Blot Analysis and Immunoblotting.
 
 
 
Western blot anal-
yses of cGKI and cAK catalytic subunits cAK
 
a
 
 and cAK
 
b
 
 in
platelets of wild-type, heterozygous, and cGKI
 
2/2
 
 mice were car-
ried out as previously reported (21). To assess the effect of cAK
and cGK activation on VASP phosphorylation, platelet-rich plasma
(PRP) was prepared as described below and incubated for 20 min
at room temperature in the presence of 0.1% DMSO (control), or
the specific activators of cAK and cGK, cBIMPS (0.1 mM; Bio-
log Life Science) and 8-pCPT-cGMP (0.1 mM; Biolog Life Sci-
ence), respectively. Platelets were then pelleted and lysed in
Laemmli buffer. VASP phosphorylation was assessed by the mo-
bility shift of phosphoVASP (9) and detected by immunoblotting
with a VASP-specific antibody (Dianova).
 
Preparation of Platelets for the Assessment of Aggregation, Shape
Change, and Serotonin Release.
 
4–8-wk-old mice of either sex
and genotype were anesthetized by chloroform inhalation and
their chests were opened. After intracardial injection of buffer A
(75 
 
m
 
l buffer [138 mM NaCl, 1.0 mM MgCl
 
2
 
, 2.9 mM KCl,
0.36 mM NaH
 
2
 
PO
 
4
 
, 20 mM Hepes, and 5 mM glucose, pH 7.4]
containing heparin [300 U/ml]), blood was collected by cardiac
puncture. Whole blood was diluted with buffer B (two parts
buffer supplemented with 30 mg/ml BSA and 30 U/ml heparin),
and centrifuged for 10 min at 100 
 
g
 
. PRP was carefully removed
and replaced by an equal volume of buffer B. After mixing gen-
tly, samples were centrifuged again for 10 min at 100 
 
g 
 
and PRP
was removed. The resulting PRP fractions were pooled and cen-
trifuged at 1,000 
 
g
 
 for 10 min. The pellet was resuspended in
buffer B to give a final density of 1–3 
 
3
 
 10
 
5
 
 platelets/
 
m
 
l.
 
Measurement of Platelet Aggregation, Shape Change, and Serotonin
Release In Vitro.
 
To evaluate the role of cGKI in the regulation
of platelet function in vitro (aggregation, shape change, and sero-
tonin release), PRP was incubated for 20 min with 0.1% DMSO
(control), 0.1 mM 8-pCPT-cGMP, or 0.1 mM cBIMPS. Aggre-
gation was started by addition of collagen (5 
 
m
 
g/ml) and followed
in an aggregometer (Chronolog). Aggregation and shape change
were measured by recording the light transmission, as previously
described (22). To assess platelet serotonin release, the PRP was
loaded with 37 MBq/ml [
 
3
 
H]5-hydroxytryptamine (5-HT; Amer-
sham Healthcare) for 1 h at 37
 
8
 
C. Thereafter, the PRP was cen-
trifuged for 10 min at 1,000 
 
g
 
, and the supernatant was removed.
The pellet was resuspended in buffer A at a density of 1–3 
 
3
 
 10
 
5
 
platelets/
 
m
 
l. After 30 min at room temperature, platelets were in-
cubated for 20 min at 37
 
8
 
C as indicated above and stimulated
with collagen (5 
 
m
 
g/ml) for 5 min. After centrifugation, the amount
of [
 
3
 
H]5-HT released into the supernatant was determined by
liquid scintillation counting.
 
Preparation of Platelets for Intravital Microscopy.
 
 
 
To
 
 
 
study plate-
let adhesion/aggregation during I/R in vivo, blood (0.8–1.0 ml)
from an anesthetized donor mouse of either genotype was col-
lected by cardiac puncture and added to a solution containing
500 
 
m
 
l Ca
 
2
 
1
 
- and
 
 
 
Mg
 
2
 
1
 
-free PBS (PAN Systems), 200 
 
m
 
l citrate
buffer (100 mM dextrose, 2.6 mM citric acid monohydrate, and
2.7 mM tri-sodium citrate dihydrate) and 15 
 
m
 
l prostaglandin
(PG)E
 
1
 
 (Sigma-Aldrich) (50 
 
m
 
g/ml). After addition of 100 
 
m
 
l fluo-
rescent dye rhodamine 6G (Sigma-Aldrich) (0.5 mg/ml) to label
platelets ex vivo, the whole blood was centrifuged for 10 min at
100 
 
g
 
 and PRP was carefully isolated. PRP was added to a solu-
tion containing 1,000 
 
m
 
l PBS (Ca
 
2
 
1 
 
and Mg
 
2
 
1
 
 free), 30 
 
m
 
l PGE
 
1
 
,
and 200 
 
m
 
l citrate buffer. After centrifugation for 10 min at 1,000 
 
g
 
,
the supernatant was removed and the resulting rhodamine-labeled
pellet was resuspended in 500 
 
m
 
l PBS (Ca
 
2
 
1 
 
and Mg
 
2
 
1
 
 free). A
50-
 
m
 
l sample of the rhodamine-labeled platelet suspension was an-
alyzed by using a flow cytometer (FACSort
 
®
 
; Becton Dickinson)
and an A
 
C
 
 T counter (Coulter Corp.) to determine the purity and
number of platelets, respectively. Labeled platelets (5.4 
 
3 
 
10
 
7
 
) of
either genotype were infused as bolus via the venous catheter.
 
Intravital Microscopy after Intestinal I/R. 
 
To evaluate the bio-
logical significance of cGKI in the regulation of platelet adhe-
sion/aggregation in vivo, fluorescent platelets were infused after
intestinal I/R and visualized in the postischemic microcirculation
by intravital fluorescence microscopy. 4–6-wk-old inbred 129sv
mice of either genotype (five to nine litter- or age-matched ani-
mals per group) were anesthetized by inhalation of isoflurane-
N
 
2
 
O (0.35 FiO
 
2
 
, 0.015 liter/liter isoflurane; Forene
 
®
 
; Abbott
GmbH). The animals were placed on a heating pad (Effenberger),
and polyethylene catheters (Portex) were implanted into the left
carotid artery and left jugular vein for continuous recording of
mean arterial blood pressure and infusion of fluorescent platelets,
respectively. After laparotomy, a segment of the jejunum was ex-
teriorized and constantly superfused with 37
 
8
 
C Ringer’s lactate.
Segmental jejunal ischemia was induced for 60 min by occluding
the supplying vessels with microsurgical clips. After reperfusion,
the intestinal segment was exposed on a mechanical stage and
platelet–platelet and platelet–endothelial cell interactions in the
postischemic microvasculature were investigated by intravital mi-
croscopy. 15 min after the onset of the reperfusion, labeled plate-
lets (5.4 
 
3 
 
10
 
7
 
) of either genotype were infused as bolus via the
venous catheter into the acceptor mouse of either genotype sub-
jected to either I/R or sham operation. Platelet concentration in
wild-type and cGKI
 
2/2
 
 mice was 0.5 
 
6 
 
0.02 
 
3 
 
10
 
6
 
 (
 
n
 
 5 
 
36) and
0.5 
 
6 
 
0.06 
 
3
 
 10
 
6
 
 (
 
n
 
 5 
 
25)/
 
m
 
l blood, respectively. During the
reperfusion, 10 nonoverlapping regions of interest from the sub-
mucosal vessels of the ischemic/reperfused segment were randomly
selected in each mouse and observed for 30 s with a modified mi-
croscope (Leitz). The microscopic images with a final magnifica-
tion on the video screen of 450
 
3
 
 were recorded by a CCD camera
(FK6990, Cohu; Prospective Measurements) connected to a
video recording system (Sony Corp.). For analysis of platelet–plate-
let and platelet–endothelial cell interactions, a computer-assisted
image analysis program (CAP IMAGE; Dr. Zeintl, University of
Heidelberg, Heidelberg, Germany) and frame-to-frame analysis of
the videotapes were used (23). All experiments were blinded, and
adherence of platelets to the surface of arterioles and venules (vessel
diameter, 15–85 
 
m
 
m) and formation of platelet aggregates in capil-
laries (diameter, 15 
 
m
 
m), arterioles, and venules (vessel diameter,
15–85 
 
m
 
m) were quantified. The number of adherent platelets was 
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assessed by counting the platelets that did not move or detach from
the endothelial surface within 15 s. Platelet adhesion is presented per
square millimeter of endothelial surface. The number of occluding
and nonoccluding aggregates was quantified within arterioles and
venules and is presented per 100 vessels. To determine platelet ag-
gregation in the capillary bed, the length (centimeter) of capillaries
occluded by fluorescent platelets was measured and calculated per
square centimeter of tissue cross-sectional area.
 
Preparation of Platelets for Renal I/R. 
 
To confirm the role of
cGKI in the regulation of I/R-induced platelet adhesion/aggre-
gation in vivo, the accumulation of 
 
111
 
I-labeled wild-type or
cGKI
 
2/2
 
 platelets was assessed in the postischemic kidney. Plate-
lets were pelleted from PRP (see above) and resuspended in 500
 
m
 
l PBS (Ca
 
2
 
1
 
 and
 
 
 
Mg
 
2
 
1 free) containing 37 MBq/ml 111I-oxine
(Amersham Healthcare). After incubation for 5 min at 378C, the
platelet suspension was centrifuged for 10 min at 1,000 g and the
supernatant was removed. The resulting pellet was washed with
2 ml PBS (Ca21 and Mg21 free) and centrifuged for 10 min at
1,000 g. After removing the supernatant, the pellet was resuspended
with 200 ml PBS (Ca21 and Mg21 free).
I/R of the Kidney.  Male wild-type 129sv mice were anesthe-
tized using intraperitoneal injection of Avertin (1.2% tribromo-
ethanol/amylalcohol in 0.9% saline solution) and placed on a heat-
ing pad for maintenance of body temperature. A polyethylene
catheter (Portex) was implanted into the left jugular vein for in-
fusion of 111I-labeled platelets and for infusion of Ringer’s lactate
to maintain euvolemia. After a midline incision of the abdomen,
the left renal artery and vein were isolated and subsequently oc-
cluded with a microsurgical clip for 30 min. 25 min after setting
occlusion, 0.2 ml of washed, 111I-labeled platelet suspension (2 3
107) of either genotype was infused via the venous catheter, and
5 min afterwards the clip was removed for reperfusion. After 25
min of reperfusion, the experiment was terminated and the kid-
ney was removed, weighed, and homogenized. The homogenate
was counted (Tri-carb 2100 TR; Packard Instrument Co.), and
the accumulation of 111I-labeled wild-type and cGKI2/2 platelets
after renal I/R was quantified as counts per minute per milligram
wet weight of the kidney (24).
Preparation of Platelets for Flow Cytometry. To study the role of
cGKI in the regulation of fibrinogen binding to agonist-stimu-
lated wild-type and cGKI2/2 platelets, blood (0.4–0.6 ml) was
collected from wild-type (n 5 7) and cGKI2/2 (n 5 5) mice by
cardiac puncture. The platelets were separated as described above
for intravital microscopy, with the exception that no rhodamine
was added. The resultant pellet was resuspended in 6 ml of a solu-
tion containing equal parts PBS with and without Ca21 and
Mg21 (PAN Systems). The purity and number of platelets were
determined using the AC T counter.
Assessment of Platelet Fibrinogen Binding In Vitro. The wild-type
or cGKI2/2 platelets were preincubated at room temperature for
2 min with either PBS (PAN Systems), the NO-donor DEA-NO
(100 nM final concentration; Alexis) or the stabile prostacyclin-
analogue iloprost (10 mM final concentration, Ilomedin; Schering
AG). After preincubation, the samples were stimulated with 0.2
U/ml mouse thrombin (Sigma-Aldrich) or PBS, and immediately
incubated for 10 min at room temperature with Alexa™ 488-
conjugated fibrinogen (12.5 mg/ml final concentration; Molecu-
lar Probes). After incubation, all samples were fixed with 1%
paraformaldehyde and the fluorescence intensity was analyzed
using a flow cytometer (FACSort®; excitation at 488 nm, emis-
sion detection at 520 nm). The platelets were identified by their
characteristic forward and sideward light scatter. Analysis of the
fluorescence properties of 10,000 platelets was performed using a
Lysis II data handling program (Becton Dickinson). The fluores-
cence intensity of unstimulated platelets, preincubated with
DEA-NO, iloprost, or PBS (,15% of thrombin-stimulated fluo-
rescence intensity), was subtracted from the fluorescence of the
corresponding thrombin-stimulated sample. Data are presented as
percentage of nonpretreated, thrombin-stimulated wild-type or
cGKI2/2 platelets.
Statistical Analysis.  All data are presented as mean 6 SEM.
Statistical differences between two means were determined by
Student’s t test or Kruskal-Wallis test (see figures). P , 0.05 was
regarded as significant, n indicates the number of animals.
Results and Discussion
cGKI2/2 Platelets Are Unresponsive to cGMP In Vitro. De-
letion of the cGKI gene abolished immunoreactive cGKI
protein without affecting the immunoreactive concentra-
tion of cAMP kinase (Fig. 1 A). Platelet activation in re-
sponse to collagen was similar in wild-type and cGKI2/2
mice (Fig. 1, C–G). In both wild-type and mutant platelets,
collagen-induced shape change, aggregation, and serotonin
release were prevented by activation of cAK by the cAK-
specific cAMP-analogue cBIMPS (Fig. 1, C–G). In contrast,
activation of cGKI by the cGMP-analogue 8-pCPT-cGMP
inhibited collagen-induced shape change, aggregation, and
serotonin release in wild-type platelets, but had no effects
on cGKI2/2 platelets. This indicates that the effects of cGMP
are mediated predominantly via activation of cGKI, whereas
other cGMP receptors, such as phosphodiesterases and cy-
clic nucleotide-gated ion channels, play a minor role in the
cGMP-dependent inhibition of platelet aggregation in
vitro. Therefore, it is very likely that NO, which is known
to elevate platelet cGMP levels (5), inhibits platelet adhe-
sion and aggregation acting via cGKI.
Cross-activation of cAK by cGMP does not appear to be
operative in platelets. The reverse mechanism (i.e., activa-
tion of cGKI by cAMP, which has been postulated to me-
diate relaxation of smooth muscle cells; reference 25) is also
not involved in the regulation of platelet function since the
specific activator of cAK, cBIMPS, elicited a similar effect
on both cGKI1/1 and cGKI2/2 platelets. We therefore con-
clude that cGMP and cAMP signaling cascades inhibit plate-
let aggregation independent from each other.
VASP Phosphorylation Is Defective in Platelets Lacking cGKI.
Several mechanisms might be involved in cGMP/cGKI-
dependent inhibition of platelet aggregation. In various cell
types, including platelets and smooth muscle cells, cGMP/
cGK lowers cytosolic Ca21 concentrations after stimulation,
thereby affecting a variety of Ca21-regulated processes (25–
28). Yet the details of cGMP/cGK-dependent regulation
of platelet Ca21 homeostasis remain to be elucidated at the
molecular level. Phosphorylation processes are likely to be
involved in the antiaggregatory effects of cGMP/cGKI on
platelets.
To date, the only well-established substrate of cGK is
VASP, a 46–50-kD vasodilator-stimulated protein, present
in high concentrations in platelets (29). In the study re-
ported here, VASP phosphorylation was assessed in wild-1258 Platelet Adhesion in cGMP Kinase I–deficient Mice
type and cGKI2/2 platelets using the mobility shift of phos-
phoVASP (9). In murine platelets, VASP is phosphorylated
in response to both cBIMPS and 8-pCPT-cGMP (Fig. 1
B). The disruption of cGKI abolished cGMP-dependent in
vivo phosphorylation of VASP in platelets without affect-
ing VASP phosphorylation in response to the cAMP ana-
logue cBIMPS. Although VASP phosphorylation correlates
well with platelet inhibition, its precise functional role has
not been established thus far. However, the subcellular lo-
cation of VASP and the association with actin filaments and
focal adhesions suggest a possible role in regulating platelet
aggregation/adhesion (30). In fact, there is evidence to sug-
gest that VASP phosphorylation is closely associated with
the inhibition of the agonist-evoked activation of the fi-
brinogen-binding site of the glycoprotein IIb–IIIa (31, 32),
supporting a role of cGKI/VASP signaling in the regula-
tion of platelet adhesion/aggregation.
cGKI Attenuates the Adhesion and Aggregation of Platelets
within the Postischemic Intestine. Growing evidence suggests
that platelets play an important role in the pathogenesis of
I/R-induced vascular injury and restenosis. Ischemia is as-
sociated with platelet accumulation early after the onset of
Figure 1. cGKI deletion affects
platelet function. (A) Western blot
analysis of cGKI and catalytic sub-
units of cAKa and cAKb in platelets
of wild-type (1/1), heterozygous
(1/2), and cGKI-deficient (2/2)
mice. (B) Phosphorylation of vaso-
dilator-stimulated phosphoprotein
(VASP) in platelets in the absence
(Ctr) and presence of 100 mM
8-pCPT-cGMP (cG) or cBIMPS
(cA). (C–G) Effect of 100 mM
8-pCPT-cGMP (cG) and 100 mM
cBIMPS (cA) on collagen-induced
platelet aggregation. Representative
traces of shape change and aggrega-
tion of wild-type (C) and cGKI2/2
(D) platelets. The arrow indicates the
addition of collagen (5 mg/ml). Sum-
mary of the effects of 8-pCPT-
cGMP (CP-cGMP) and cBIMPS on
shape change (E), aggregation (F),
and secretion of 5-hydroxytryp-
tamine (G) in cGKI1/1 and cGKI2/2
platelets. Values are presented as
mean  6  SEM of four to six animals.
*P , 0.05, Student’s t test.1259 Massberg et al.
reperfusion (17). Clinical and experimental studies have in-
dicated that platelet adhesion and aggregate formation and
the release of proinflammatory mediators from activated
platelets in response to ischemia may impair restoration of
nutritive blood supply during reperfusion (33, 34). Although
activation of cGKI attenuates platelet aggregation in vitro,
the significance of the NO/cGMP/cGKI pathway in the
homeostasis of platelet adhesion/aggregation during I/R in
vivo has not been clearly defined thus far. The biological
role of cGKI might be questioned, since the deficit in
cGKI could be compensated by endothelium-derived pros-
tacyclin signaling through the unperturbed cAK pathway
(12). Therefore, to study the physiological relevance of cGKI
in vivo, we determined platelet adherence and aggregation
within the microcirculation of an ischemic/reperfused seg-
ment of the jejunum using intravital video microscopy.
Wild-type and cGKI2/2 mice (acceptor) were subjected to
intestinal ischemia (60 min). After reperfusion, fluorescent
wild-type and cGKI2/2 platelets were infused and visual-
ized within the intestinal submucosa (arterioles, capillaries,
and venules) by intravital fluorescence microscopy.
Since platelet adhesion to the injured vessel surface rep-
resents an early step in the process of platelet accumulation/
aggregation, we first determined the number of adherent
platelets within arterioles and postcapillary venules of the
postischemic submucosal microcirculation. Under control
conditions without I/R (sham), wild-type platelets did not
interact with wild-type endothelium (Fig. 2). In contrast,
numerous platelets were found firmly attached to the vas-
cular wall of both arterioles and postcapillary venules in re-
sponse to I/R (45 6 18 and 43 6 24 adherent platelets/
mm2, respectively; Figs. 2 and 3, A and B). To assess the
role of cGKI in the regulation of platelet function in vivo,
cGK2/2 platelets were transfused into cGK-deficient mice
after I/R. The loss of cGKI drastically enhanced postisch-
emic platelet–endothelial cell interactions. Within both
arterioles and venules, the number of adherent platelets was
increased four- to sixfold when compared with wild-type
animals. Under control conditions, no adhesion of cGKI2/2
platelets to the vessel wall was observed, indicating that a
pathological stimulus, such as I/R, is required to induce
platelet adhesion in cGKI2/2 mice.
Because platelets, endothelial cells, and smooth muscle
cells express cGKI, we wanted to clarify whether cGKI ex-
pressed by platelets or present in the vascular wall is neces-
sary to inhibit platelet adhesion during postischemic reper-
fusion. To determine the contribution of platelet cGKI,
cGKI2/2 platelets were infused into wild-type mice. The
isolated loss of platelet cGKI dramatically enhanced I/R-
induced platelet adhesion to the vascular wall of wild-type
animals: 290 6 45 and 181 6 28 platelets were found
firmly attached per square millimeter endothelial surface of
arterioles and venules, respectively (Figs. 2 and 3, A and B).
Therefore, platelet adhesion is enhanced to a similar extent,
independent of whether platelets alone or both platelets
and vascular wall lack cGKI. Accordingly, I/R-induced ad-
hesion of wild-type platelets was not increased in cGKI
null mutants as compared with wild-type recipients (Figs. 2
Figure 2. Photomicrographs of
the postischemic intestinal microcir-
culation. Platelet–endothelial cell
and platelet–platelet interactions are
visualized by intravital fluorescence
microscopy. Representative pic-
tures from postischemic submucosal
arterioles are presented. Sham-oper-
ated (sham) animals without I/R
served as controls. Donor, animal
genotype of the donor platelets; ac-
ceptor, genotype of the recipient,
subjected to I/R.1260 Platelet Adhesion in cGMP Kinase I–deficient Mice
and 3 A). This demonstrates that the cGKI expressed in en-
dothelium and smooth muscle cells plays a minor role in
the regulation of platelet adhesion dynamics during I/R.
During reperfusion, adherent platelets may subsequently
aggregate leading to luminal narrowing and complete vas-
cular (re-)occlusion, resulting in additional ischemia of the
supplied tissue (18–20). To evaluate the participation of
cGKI in the regulation of platelet aggregation in vivo, we
quantified the presence of platelet aggregates in arterioles
and venules of the postischemic jejunal segment. The num-
ber of occluding and nonoccluding aggregates in arterioles
and venules was assessed within 10 randomly selected re-
gions of interest and is presented per 100 vessels (Figs. 2
and 3, D and E). Whereas aggregation of wild-type or
cGKI2/2 platelets was virtually absent under control condi-
tions, platelets deficient in cGKI showed a very strong ten-
dency to aggregate in response to I/R. In postischemic ar-
terioles, 2–5 occluding and 17–26 nonoccluding aggregates
were observed per 100 vessels when cGKI2/2 platelets were
transfused into wild-type or cGKI2/2 mice, respectively
(Fig. 3, D and E). Likewise, the absence of cGKI in platelets
enhanced aggregation in postcapillary venules (not shown).
In contrast, no occluding or nonoccluding aggregates were
detected when both platelets and the vascular wall expressed
cGKI (Fig. 3, D and E), indicating that cGMP/cGKI signal-
ing pathways regulate both platelet adhesion and aggrega-
tion. To assess the role of cGKI present in endothelial cells
and vascular smooth muscle, wild-type platelets were trans-
fused into cGKI2/2 mice (Fig. 3, D and E). However, the
absence of cGKI in the vascular wall did not significantly
enhance the aggregation of wild-type platelets in arterioles
or venules, suggesting that endothelial cell and smooth mus-
cle cGKI are not involved in the regulation of platelet ag-
gregation in vivo.
Platelet aggregation in cGKI mutants was not confined
to arterioles and venules, but was also frequently observed
in capillaries (diameter, 10 mm). To assess the extent of plate-
let aggregation in the capillary bed of the postischemic sub-
mucosa, the length (centimeters) of capillaries occluded by
fluorescent platelets was measured and calculated per square
Figure 3. Summary of ischemia–reperfusion experi-
ments. The adherent platelets in arterioles (A) and
venules (B) were quantified and defined as platelets that
did not move or detach from the endothelial surface
within 15 s. The number of adherent platelets per
square millimeter of endothelial surface, calculated
from the diameter and length of the observed vessel
segment, is presented. (C) Aggregates in capillaries (di-
ameter , 10 mm) were quantified as length of oc-
cluded capillaries (centimeters) per square centimeter
tissue cross-sectional area. (D) Occluding and (E) non-
occluding platelet aggregates per 100 arterioles (diame-
ter, 15 mm) of a postischemic segment of the jejunum.
(F) Accumulation of 111Indium-labeled platelets in the
kidney after I/R. All values are mean 6 SEM, derived
from five to nine animals per group. *P , 0.05 by the
Kruskal-Wallis test.1261 Massberg et al.
centimeter tissue cross-sectional area (Figs. 2 and 3 C).
Platelet aggregates in capillaries were nearly absent after trans-
fusion of wild-type platelets into wild-type mice or cGKI
mutants. In contrast, aggregation of cGKI2/2 platelets in post-
ischemic capillaries was a prominent phenomenon, indepen-
dent of whether or not the vascular wall expressed cGKI.
Hence, platelet adhesion and platelet aggregation in arte-
rioles, capillaries, and venules are drastically enhanced when
the platelets lack cGKI. In contrast, the absence of the en-
dothelial/smooth muscle cGKI has no significant effects on
homotypic platelet–platelet or heterotypic platelet–endo-
thelium interactions in response to I/R. This indicates that
under pathophysiological conditions, such as I/R, NO acts
via the cGKI present in platelets to regulate platelet adhe-
sion and aggregation in vivo. Although endothelial cells are
considered to be the major source of NO, in particular
under conditions associated with platelet activation, plate-
let-derived NO also plays an important role in regulating
platelet aggregation and platelet recruitment (35). During
aggregation, the NO release by platelets is significantly in-
creased (35). This increase in NO formation can act via
guanylyl cyclase to activate platelet cGKI. Therefore, plate-
lets appear to have the ability to self-regulate their adhesion
and aggregation upon activation by an autocrine/paracrine
mechanism in which activated platelets release NO that
acts on platelet cGKI to attenuate both adhesion and aggre-
gation.
It appears noteworthy that, under physiological condi-
tions without I/R, platelet aggregation in arterioles, capil-
laries, and venules was absent in both wild-type animals
and cGKI2/2 mutants (not shown). This indicates that both
endothelial cells and platelets are in an antiadhesive/antico-
agulant state under physiological conditions and acquire a
proadhesive/procoagulant phenotype in response to I/R.
Increased Platelet Accumulation after Renal I/R In Vivo.
To evaluate whether the observed increase in postischemic
platelet adhesion and aggregation due to the loss of platelet
cGKI is confined to the intestine or rather a more general
defect in platelet function, we analyzed the accumulation
of wild-type and cGKI2/2 platelets after I/R of the kidney.
Wild-type animals were laparotomized, and the left renal
artery and vein were cross-clamped for 30 min using micro-
surgical clips. 5 min before reperfusion, washed 111I-labeled
platelets were infused via a catheter implanted into the left
jugular vein. After 25 min of reperfusion, the left kidney
was excised and platelet accumulation was quantified as
counts per minute per milligram wet weight. Renal I/R
induced the accumulation of 111Indium-labeled wild-type
platelets in the postischemic wild-type kidney. However,
platelets lacking cGKI exhibited a 46% higher accumula-
tion in the wild-type kidney after I/R when compared
with wild-type platelets (Fig. 3 F; P , 0.05), suggesting
that cGKI inhibits postischemic platelet accumulation inde-
pendent of the organ studied.
cGKI Inhibits Fibrinogen Binding to Thrombin-stimulated
Platelets. The molecular mechanisms underlying cGKI-
dependent inhibition of platelet adhesion/aggregation dur-
ing I/R in vivo are as yet unclear. There is growing evi-
dence indicating that I/R is associated with an activation of
the platelet fibrinogen receptor, the glycoprotein (GP) IIb–
IIIa (36). Binding of fibrinogen to the activated form of the
platelet GP IIb–IIIa integrin complex plays a critical role in
the process of platelet adhesion/aggregation (37, 38). Al-
though both NO and cGMP have been shown to interfere
with agonist-evoked activation of the GP IIb–IIIa (31, 39),
the exact role of cGKI in the inhibition of GP IIb–IIIa ac-
tivation has not been identified thus far. To determine
whether cGKI mediates NO/cGMP-dependent regulation
of GP IIb–IIIa function, we have investigated the effects of
NO on agonist-induced fibrinogen binding to wild-type
and cGKI2/2 platelets in vitro. In wild-type platelets, pre-
treatment with NO decreased thrombin-induced fibrinogen
binding by z46% (Fig. 4). In contrast, in platelets lacking
cGKI, the response to NO was nearly absent (P , 0.05).
Hence, cGKI-dependent inhibition of the GP IIb–IIIa
adhesion complex is involved in the regulation of platelet
adhesion/aggregation by NO/cGMP in vivo. The loss of
platelet cGKI does not affect the ability of platelets to re-
spond to prostacyclin. Preincubation with iloprost reduced
agonist-induced fibrinogen binding to both wild-type and
cGKI2/2 platelets by z40%. Therefore, the inability of the
endogenous cAMP kinase-activating system to compensate
for the loss of cGKI in vivo is not due to alterations in the
response of cGKI2/2 platelets to exogenous prostacyclin.
In conclusion, we have demonstrated that platelet cGKI
attenuates agonist-induced platelet activation, fibrinogen
Figure 4. Summary of flow cytometric experiments. Platelet samples,
preincubated with iloprost or DEA-NO, were stimulated with mouse
thrombin or PBS in the presence of Alexa™ 488–conjugated fibrinogen.
Binding of the fluorescent fibrinogen to wild-type and cGKI2/2 platelets
was assessed by flow cytometry. The fluorescence intensity obtained from
nonstimulated platelets pretreated with PBS, DEA-NO, or iloprost was
subtracted from the fluorescence of thrombin-stimulated platelets, prein-
cubated with PBS, DEA-NO, or iloprost, respectively. Fibrinogen-bind-
ing to thrombin-stimulated wild-type or cGKI2/2 platelets in the pres-
ence of prostacyclin or DEA-NO was calculated as percentage of the
nonpretreated, thrombin-stimulated control sample. All values are mean 6
SEM, derived from five to seven animals per genotype. *P ,  0.05 by the
Student’s t test.1262 Platelet Adhesion in cGMP Kinase I–deficient Mice
binding, and aggregation in vitro. Moreover, the loss of
cGKI in platelets is associated (a) with an increase in plate-
let accumulation in the postischemic kidney and (b) with a
significant enhancement of both platelet adhesion and ag-
gregation in the postischemic intestinal microvasculature in
vivo. The platelet cAMP/cAK signaling cascade does not
compensate for the loss of cGKI under pathophysiological
conditions. Platelets are known to release NO upon activa-
tion; therefore, an autocrine/paracrine signaling cascade,
including platelet-derived NO and platelet cGKI, is likely
to be involved in the regulation of platelet adhesion and
aggregation under physiological and, in particular, patho-
physiological conditions. Since the accumulation and ag-
gregation of platelets after endothelial injury is a common
pathophysiological mechanism underlying many of the
most important diseases, including myocardial infarction,
angina pectoris, thrombotic stroke, and peripheral vascular
insufficiency, specific activators of platelet cGKI might
present a powerful strategy aimed at the prevention of I/R
injury.
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